Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815974 | 0.87 | MT-CO2 (0.33) | CTSDCTSLCTSBCTSSMT-CO2 | |
| SCHEMBL16092585 | 0.86 | HDAC6 (0.33) | CTSDCTSLCTSBCTSSMT-CO2 | |
| SCHEMBL10042568 | 0.85 | HDAC6 (0.32) | HDAC6HDAC1HDAC2 | |
| SCHEMBL13747089 | 0.84 | MT-CO2 (0.34) | MT-CO2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL2578067 | 0.84 | CA14 (0.33) | MT-CO2NFKB1NFKB2RELAHDAC6 | |
| SCHEMBL16092920 | 0.83 | HDAC6 (0.34) | MT-CO2HDAC6HDAC1HDAC2 | |
| SCHEMBL10042493 | 0.83 | HDAC1 (0.35) | HDAC6HDAC1HDAC2 | |
| SCHEMBL417618 | 0.82 | NR1D1 (0.32) | — | |
| SCHEMBL10389291 | 0.80 | NAMPT (0.33) | NFKB1NFKB2RELA | |
| SCHEMBL4038414 | 0.79 | SMN1; SMN2 (0.38) | MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
| WO-2024259007-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4267590-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ONCOARENDI THERAPEUTICS S.A. (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | FOB SYNTHESIS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8232268-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232268-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC., (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | FOB SYNTHESIS, INC., (US) | 2010-06-24 | — | — | US | disclosed |
| US-7683049-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683049-B2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB SYNTHESIS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-2127650-A2 | Carbapenem antibacterials with gram-negative activity and processes for their preparation | FOB Synthesis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008060767-A2 | MACROCYCLIC BENZOFUSED PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | CTSD 1074/4885CTSL 2844/4885CTSB 1832/4885 |
| US-20120296084-A1 | Carbapenem Antibacterials with Gram-Negative Activity and Processes for Their Preparation | MGAM, GSK3B, GSK3A | CTSD 2226/4885CTSL 1733/4885CTSB 1149/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | CTSD 847/4885CTSL 320/4885CTSB 692/4885 |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | CTSD 2424/4885CTSL 1343/4885CTSB 2777/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | CTSD 1179/4885CTSL 101/4885CTSB 355/4885 |
| US-20100160284-A1 | CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY AND PROCESSES FOR THEIR PREPARATION | MGAM, GSK3B, GSK3A | CTSD 2226/4885CTSL 1733/4885CTSB 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.